Patents by Inventor Mary Jackson
Mary Jackson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139148Abstract: The present disclosure provides compositions and methods related to the treatment of non-tuberculous mycobacterial infections in a subject. In particular, the present disclosure provides compositions comprising an anti-malarial agent and associated methods of treating and/or preventing a non-tuberculous mycobacterial infection in a subject using the composition.Type: ApplicationFiled: June 10, 2022Publication date: May 2, 2024Inventors: Mary Jackson, Juan Belardinelli
-
Patent number: 11154977Abstract: A system, method, and apparatus may be provided for gripping a handheld instrument. A spherical body may be configured to support at least a portion of the handheld instrument. A working portion of the handheld instrument may be oriented below a body of the gripping device. A top opening may be provided at a top of the gripping device, wherein the top opening may be configured to receive a portion of the handheld instrument. A bottom opening at the bottom of the gripping device may be provided, wherein the bottom opening may be configured to receive a portion of the handheld instrument. A convex surface may receive a palmar surface of a user's fingers, thumb, and/or hand.Type: GrantFiled: August 1, 2019Date of Patent: October 26, 2021Inventor: Janet Mary Jackson-Coty
-
Publication number: 20210031355Abstract: A system, method, and apparatus may be provided for gripping a handheld instrument. A spherical body may be configured to support at least a portion of the handheld instrument. A working portion of the handheld instrument may be oriented below a body of the gripping device. A top opening may be provided at a top of the gripping device, wherein the top opening may be configured to receive a portion of the handheld instrument. A bottom opening at the bottom of the gripping device may be provided, wherein the bottom opening may be configured to receive a portion of the handheld instrument. A convex surface may receive a palmar surface of a user's fingers, thumb, and/or hand.Type: ApplicationFiled: August 1, 2019Publication date: February 4, 2021Inventor: Janet Mary Jackson-Coty
-
Publication number: 20200331897Abstract: The present application provides detectable compounds useful for identifying compounds that bind (e.g., inhibit) MmpL3. Methods of identifying compounds that bind and/or inhibit MmpL3 are also provided.Type: ApplicationFiled: February 21, 2020Publication date: October 22, 2020Applicants: Creighton University, Colorado State University Research FoundationInventors: Jeffrey North, Amitkumar Navinchandra Pandya, Mary Jackson, Wei Li, Mercedes Gonzalez-Juarrero
-
Patent number: 7527788Abstract: Antibodies that bind to the M. tuberculosis Des protein are provided.Type: GrantFiled: February 21, 2006Date of Patent: May 5, 2009Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 7264815Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: GrantFiled: January 4, 2006Date of Patent: September 4, 2007Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Publication number: 20060241291Abstract: Antibodies that bind to the M. Tuberculosis des gene are provided.Type: ApplicationFiled: February 21, 2006Publication date: October 26, 2006Inventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 7071320Abstract: The use of genetic methodology based on the fusion of the proteins with the alcaline phosphatase (Lim et al., 1995) has allowed the isolation of a new exported protein of M. tuberculosis. In the present article, first of all the isolation of a gene encoding this exported protein called DES is described as well as its characterization and its distribution among the different mycrobacterial species. It is notably shown that the protein has in its primary sequence amino acids only found at the level of active sites of enzymes of class II diiron-oxo proteins family. Among the proteins of this family, DES protein of M. tuberculosis does not present significative homologies with stearoyl ACP desaturases. Secondly, the antigenic feature of this protein has been studied. For this, DES protein of M. tuberculosis has been overexpressed in E. coli under recombinant and purified protein form from this bacterium. The reactivity of tuberculous patients sera infected by M. tuberculosis or M.Type: GrantFiled: February 20, 2003Date of Patent: July 4, 2006Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 7067136Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: GrantFiled: August 10, 2004Date of Patent: June 27, 2006Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Publication number: 20060099221Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: ApplicationFiled: January 4, 2006Publication date: May 11, 2006Inventors: Mary Jackson, Brigitte Gicquel
-
Publication number: 20050244840Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: ApplicationFiled: August 10, 2004Publication date: November 3, 2005Inventors: Mary Jackson, Brigitte Gicquel
-
Publication number: 20050032107Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: ApplicationFiled: August 10, 2004Publication date: February 10, 2005Inventors: Mary Jackson, Brigitte Gicquel
-
Publication number: 20040142332Abstract: The use of genetic methodology based on the fusion of the proteins with the alcaline phosphatase (Lim et al., 1995) has allowed the isolation of a new exported protein of M. tuberculosis. In the present article, first of all the isolation of a gene encoding this exported protein called DES is described as well as its characterization and its destribution among the different microbacterial species. It is notably shown that the protein has in its primary sequence amino acids only found at the level of active sites of enzymes of class II diiron-oxo proteins family. Among the proteins of this family, DES protein of M. tuberculosis does not present significative homologies with stearoyl ACP desaturases. Secondly, the antigenic feature of this protein has been studied. For this, DES protein of M. tuberculosis has been overexpressed in E. coli under recombinant and purified protein from from this bacterium. The reactivity of tuberculous patients sera infected by M. tuberculosis or M.Type: ApplicationFiled: February 20, 2003Publication date: July 22, 2004Applicant: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Publication number: 20030157589Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: ApplicationFiled: March 10, 2003Publication date: August 21, 2003Inventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 6582925Abstract: The use of genetic methodology based on the fusion of the proteins with the alcaline phosphatase (Lim et al., 1995) has allowed the isolation of a new exported protein of M. tuberculosis. In the present article, first of all the isolation of a gene encoding this exported protein called DES is described as well as its characterization and its distribution among the different mycobacterial species. It is notably shown that the protein has in its primary sequence amino acids only found at the level of active sites of enzymes of class II diiron-oxo proteins family. Among the proteins of this family, DES protein of M. tuberculosis does not present significative homologies with stearoyl ACP desaturases. Secondly, the antigenic feature of this protein has been studied. For this, DES protein of M. tuberculosis has been overexpressed in E. coli under recombinant and purified protein form from this bacterium. The reactivity of tuberculous patients sera infected by M. tuberculosis or M.Type: GrantFiled: April 20, 1999Date of Patent: June 24, 2003Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 6573064Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: GrantFiled: October 28, 1999Date of Patent: June 3, 2003Inventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 6551808Abstract: The present invention relates to the isolation of a new gene, des, which encodes a M. tuberculosis protein named DES. The des gene appears to be conserved among different Mycobacteria species. The amino acid sequence of the DES protein contains two sets of motifs that are characteristic of the active sites of enzymes from the class II diiron-oxo protein family. Among this family of proteins, DES shares significant homology with soluble stearoyl-ACP desaturases. DES is a highly antigenic protein, which is recognized by human sera from patients infected with M. tuberculosis and M. leprae but not by sera from tuberculous cattle. Thus, the DES protein provides a useful tool for the serodiagnostic analysis of tuberculosis.Type: GrantFiled: December 7, 2000Date of Patent: April 22, 2003Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Publication number: 20020192781Abstract: The present invention relates to the isolation of a new gene, des, which encodes a M. tuberculosis protein named DES. The des gene appears to be conserved among different Mycobacteria species. The amino acid sequence of the DES protein contains two sets of motifs that are characteristic of the active sites of enzymes from the class II diiron-oxo protein family. Among this family of proteins, DES shares significant homology with soluble stearoyl-ACP desaturases. DES is a highly antigenic protein, which is recognized by human sera from patients infected with M. tuberculosis and M. leprae but not by sera from tuberculous cattle. Thus, the DES protein provides a useful tool for the serodiagnostic analysis of tuberculosis.Type: ApplicationFiled: December 7, 2000Publication date: December 19, 2002Applicant: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Publication number: 20010024653Abstract: This invention provides recombinant mycobacterium strains of pathogenic origin that have been attenuated by the inactivation of a gene coding for a metabolic protein, specifically a gene coding for a protein necessary for the biosynthesis of a purine or a pyrimidine base, and more precisely, the purC gene that codes for an enzyme of the metabolic pathway of purine biosynthesis. The recombinant mycobacterium of this invention have a reduced capacity to propagate in a mammalian host, but remain viable in the host for a period of time sufficient to induce an protective immune response against the natural pathogenic mycobacterium counterpart.Type: ApplicationFiled: May 9, 2001Publication date: September 27, 2001Applicant: Institut PasteurInventors: Bridgitte Gicquel, Christophe Guilhot, Mary Jackson
-
Patent number: 6261568Abstract: This invention provides recombinant mycobacterium strains of pathogenic origin that have been attenuated by the inactivation of a gene coding for a metabolic protein, specifically a gene coding for a protein necessary for the biosynthesis of a purine or a pyrimidine base, and more precisely, the purC gene that codes for an enzyme of the metabolic pathway of purine biosynthesis. The recombinant mycobacterium of this invention have a reduced capacity to propagate in a mammalian host, but remain viable in the host for a period of time sufficient to induce an protective immune response against the natural pathogenic mycobacterium counterpart.Type: GrantFiled: June 11, 1998Date of Patent: July 17, 2001Assignee: Institut PasteurInventors: Bridgitte Gicquel, Christophe Guilhot, Mary Jackson